According to reports, clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin have been halted following the termination of the company's partnership with its partner. "The prohibition was taken out as a response of a statement provided to Anvisa on friday (July 23) by the indian firm Bharat Biotech Limited International," the Brazilian health authority stated on Friday.

The news comes only a day after Bharat Biotech announced the termination of a memorandum of agreement to market Covaxin for Precisa Medicamentos in Brazil. Bharat Biotech, on the other hand, did not say why.

“With immediate effect, the Company has dissolved the aforementioned MOU. Despite this, Bharat Biotech will remain to work closely with ANVISA, the Brazilian medical regulatory agency, to finish the regulatory clearance process for Covaxin,” the firm stated on Friday.

Bharat Biotech's Brazilian partner, Precisa Medicamentos, assisted, guided, and supported the company with regulatory filings, licence, distribution, insurance, and the conduct of Phase 3 clinical studies.

The agreement was terminated when a dispute arose over an arrangement with the Brazilian government to deliver 20 million vials of vaccine In Brazil, there have been suspicions of anomalies in the govt 's efforts to purchase 20 million vaccinations through Precisa.

మరింత సమాచారం తెలుసుకోండి:

Covaxin

Sachin

24/07/2021 01:15 PM